Citi analyst Samantha Semenkow initiated coverage of Biohaven (BHVN) with a Buy rating and $28 price target The company is therapies across neuroscience, immunology, and oncology, the analyst tells investors in a research note. Citi views the stock’s valuation as “de-risked” into the troriluzole FDA action date.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: